Navigation Links
InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
Date:10/3/2009

Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of their diagnostic ad preclinical grade material very fast and in highest quality, including authentic human glycosylation patterns, using the novel and proprietary CAP-TTM transient expression system.

CAP-TTM Technology is based on CAP cells, the stable cell line from CEVEC. The non-tumor origin cells have high expression rates of human proteins and grow in serum-free suspension culture and post-translational modifications are human-like. Process times are reduced by means of large-scale transient transfection.

After launching our new transient cell in the US market we are delighted to have now our first customers in Europe not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, e.g. HEK 293 freestyle and others, while offering highest quality human like proteins, we offer our customers a unique state of the art cell line, Wolfgang Kintzel, CCO of CEVEC Pharmaceuticals GmbH states.

Rainer Lichtenberger, CEO of CEVEC, adds. Because posttranslational modifications play a significant role for the bioactivity of recombinant proteins it is of crucial importance to produce proteins with human-like glycosylation and sialylation. With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only CEVEC is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This license agreement contributes significantly to CEVECs
'/>"/>

b3c newswire

Page: 1 2 3

Related biology news :

1. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
2. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
3. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
4. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
5. Bacteria from sponges make new pharmaceuticals
6. MSU licenses plant oil enhancement technology to BASF Plant Science
7. UGA licenses technology to make fuel from dead forests and agricultural waste
8. UGA licenses new Bermuda grass that thrives in sun and shade
9. WARF signs license agreement with Pfizer for human embryonic stem cells
10. FluChip technology licensed to combat deadly flu virus
11. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... in German . ... uses the refraction of X-rays through a specimen instead ... this method are often of much higher quality than ... of Prof. Franz Pfeiffer are particularly interested in developing ... including X-ray phase-contrast imaging. One main goal is to ...
(Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... Island of New Zealand is marked at approximately 38 S ... line". This region forms the southern distributional limit of many ... number of endemic plants are found there. Ecologists have recently ... the "kauri line". Wetlands serve vital ecological functions by ...
... and from Berkeley have used metal complexes to modify ... Chemical Society , they report for the first time ... "With this work, we have laid the molecular foundation ... Stoll from the Faculty of Chemistry and Biochemistry at ...
... MAResearchers from Brigham and Women,s Hospital (BWH) have made a ... The team, led by Thomas S. Kupper, MD, chair of ... that high expression of a cell-signaling molecule, known as interleukin-9, ... findings will be published online in the July 8, 2012 ...
Cached Biology News:A new species of wirerush from the wetlands in northern New Zealand 2A new avenue to better medicines: Metal-peptide complexes 2Researchers discover molecule in immune system that could help treat dangerous skin cancer 2
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... in part) in, into or from any jurisdiction where to ... of such jurisdiction.  Shire plc ("Shire" or the ... Bloomberg article this afternoon.  Shire confirms it has held a ... being made by Shire without the prior agreement or approval ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... DCGN ) announced that on February 2, 2009, it ... "Panel") stating that the Panel,will transfer the listing of ... Nasdaq Capital Market, effective at the open of the ... Market, which is,one of the three market tier designations ...
... UPI ),a medical device company that develops, manufactures ... reported financial,results for the third quarter of fiscal 2009 ... quarter of fiscal 2009 were $3.4 million versus $3.7,million ... "As we discussed in conjunction with the ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
Cached Biology Technology:deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market 2deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market 3Uroplasty Reports Third Quarter Fiscal 2009 Results 2Uroplasty Reports Third Quarter Fiscal 2009 Results 3Uroplasty Reports Third Quarter Fiscal 2009 Results 4Uroplasty Reports Third Quarter Fiscal 2009 Results 5Uroplasty Reports Third Quarter Fiscal 2009 Results 6Uroplasty Reports Third Quarter Fiscal 2009 Results 7Uroplasty Reports Third Quarter Fiscal 2009 Results 8Uroplasty Reports Third Quarter Fiscal 2009 Results 9Uroplasty Reports Third Quarter Fiscal 2009 Results 10Uroplasty Reports Third Quarter Fiscal 2009 Results 11Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9